编程心室刺激:风险分层和指导抗心律失常疗法
Timothy M Markman1, Francis E Marchlinski1, David J Callans1
1Cardiovascular Division, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
JACC. Clinical electrophysiology
|April 25, 2024
概括
编程腹腔刺激 (PVS) 有助于心肌病的风险分层,并指导抗心律失常疗法,包括导管切除. 优化PVS协议可以提高其在预测心脏突然死亡和评估治疗有效性的准确性.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 心脏节律失常症 心脏节律失常症
背景情况:
- 编程腹腔刺激 (PVS) 在患有心肌病的患者中诱导腹腔动心 (VT) 是至关重要的.
- 它有助于对心脏突然死亡的风险分层,并评估抗心律失常疗法的疗效,特别是导管切除.
- PVS程序参数和积极结果定义影响测试的灵敏度和特异性.
研究的目的:
- 审查PVS在不同患者群体风险分层中的历史和当前作用.
- 建议未来的研究方向,以优化PVS的敏感性和特异性.
- 讨论在导管切除期间和之后的PVS应用及其在指导管理决策中的作用.
主要方法:
- 对编程腹腔刺激 (PVS) 的历史数据和当前文献的审查.
- 对程序修改 (节奏周期长度,外刺激,位置) 的分析和积极结果的定义.
- 在缺血性和非缺血性心肌病,突然心脏死亡风险和抗心律失常治疗评估PVS的评估.
主要成果:
- PVS是风险分层和评估心肌病治疗疗效的宝贵工具.
- 修改PVS协议可以改变对VT诱导的测试灵敏度和特异性.
- 非侵入性编程刺激可以预测反复的VT,并为管理策略提供信息.
结论:
- 在治疗心室心律失常和心肌病的患者中,PVS扮演着重要的角色.
- 优化PVS协议和定义对于准确的风险分层和治疗评估至关重要.
- 未来的研究应该专注于改进PVS策略,以最大限度地提高其临床效用.
相关概念视频
Disturbances in Heart Rhythm
945
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
945
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
980
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
980
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
741
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
741
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Mechanism of Cardiac Arrhythmias
917
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
917
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
832
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832


